| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Enrollment in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway |
| 22 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Effective as of October 20, 2026, the board of directors (the “Board”) of MBX Biosciences, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed P... |
| 27 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
One-year data demonstrated sustained benefit of once-weekly canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism; Phase 3 pivotal trial now recruiting |
| 13 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 12 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism |
| 05 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
On June 4, 2026, MBX Biosciences, Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting"). As further described under Item 5.07 below, the Company's stockholders approved the election of two Class II dire... |
| 11 May 2026 |
8-K: Regulation FD Disclosure; Other Events
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026 |
| 12 Mar 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA |
| 09 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism |
| 27 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
| 05 Feb 2026 |
8-K: Other Events
On February 4, 2026, MBX Biosciences, Inc. (the “Company”), closed on the sale and issuance of an aggregate of 2,250,986 shares of its common stock (the "Shares") at a volume weighted average price per share of $38.76 for gross proceeds ... |
| 22 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
CARMEL, Ind., Jan. 22, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the trea... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Reported positive topline results from the Phase 2 Avail™ trial of once-weekly canvuparatide in hypoparathyroidism (HP) |
| 26 Sep 2025 |
8-K: Entry into a Material Definitive Agreement
As Representatives of the several Underwriters listed in Schedule 1 hereto |
| 22 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension |
| 04 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
Preclinical data support the potential for improved weight loss and tolerability with once-monthly administration of MBX 4291 |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Topline results for the Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism on track for Q3 2025 |
Loading...